| Cvs Pharmacy # 01901 | |
| 35 N Main Street, Bangor, Pennsylvania 18013 | |
| (610) 588-9425 |
| Name | Cvs Pharmacy # 01901 |
|---|---|
| Organization Name | Pennsylvania Cvs Pharmacy, L.l.c. |
| Location | 35 N Main Street, Bangor, Pennsylvania 18013 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (610) 588-9425 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
University of Houston pharmacy students wrapped up the spring semester with awards for excellence in professional service, clinical skills and disease management, earning kudos at the state level from the Texas Society of Health-System Pharmacists.
Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.
Today's headlines include reports on how health reform is playing a role in presidential politics, both during the Democratic National Convention in Charlotte, N.C., and in a new GOP campaign ad.
Sonomax Hearing Healthcare Inc. is pleased to announce that it has signed a five year license agreement with Hearing Coach Africa (Pty). The agreement for V3 hearing protectors specifies quarterly commitments over five years, totaling a minimum of $1,000,000. The agreement is renewable for an additional 5 years if all contractual conditions and minimum quarterly commitments are met.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
› Verified 3 days ago
| NPI Number | 1235233081 |
| Organization Name | PENNSYLVANIA CVS PHARMACY, L.L.C. |
| Doing Business As | CVS PHARMACY #01901 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 35 N Main St, Bangor, PA 18013 |
| Phone Number | 610-588-4695 |
News Archive
University of Houston pharmacy students wrapped up the spring semester with awards for excellence in professional service, clinical skills and disease management, earning kudos at the state level from the Texas Society of Health-System Pharmacists.
Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.
Today's headlines include reports on how health reform is playing a role in presidential politics, both during the Democratic National Convention in Charlotte, N.C., and in a new GOP campaign ad.
Sonomax Hearing Healthcare Inc. is pleased to announce that it has signed a five year license agreement with Hearing Coach Africa (Pty). The agreement for V3 hearing protectors specifies quarterly commitments over five years, totaling a minimum of $1,000,000. The agreement is renewable for an additional 5 years if all contractual conditions and minimum quarterly commitments are met.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
› Verified 3 days ago
News Archive
University of Houston pharmacy students wrapped up the spring semester with awards for excellence in professional service, clinical skills and disease management, earning kudos at the state level from the Texas Society of Health-System Pharmacists.
Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.
Today's headlines include reports on how health reform is playing a role in presidential politics, both during the Democratic National Convention in Charlotte, N.C., and in a new GOP campaign ad.
Sonomax Hearing Healthcare Inc. is pleased to announce that it has signed a five year license agreement with Hearing Coach Africa (Pty). The agreement for V3 hearing protectors specifies quarterly commitments over five years, totaling a minimum of $1,000,000. The agreement is renewable for an additional 5 years if all contractual conditions and minimum quarterly commitments are met.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
› Verified 3 days ago
Vision Source Bangor Type: Medicare Supplier Location: 385 Bangor Junction Rd, Bangor, Pennsylvania 18013 Phone: (610) 588-0129 | |
Cvs Pharmacy # 01901 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 35 N Main Street, Bangor, Pennsylvania 18013 Phone: (610) 588-9425 | |
Rite Aid Pharmacy 01384 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 450 Blue Valley Dr, Bangor, Pennsylvania 18013 Phone: (610) 863-6101 |